PTC Therapeutics (PTCT) Q3 Revenues Beat

October 28, 2021 4:01 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.89), $0.49 worse than the analyst estimate of ($1.40). Revenue for the quarter came in at $138.7 million versus the consensus estimate of $126.44 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities